CDKN2A and neoplasm: Furthermore, the study also revealed a three-panel gene set (CDKN2A, CTSV, and FOXM1) that can accurately predict tumor progression and suggested as potential prognostic biomarker(s) for bladder cancer, which could aid in clinical decision making.